MedTrace Logo

Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia

NCT02992938 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-12-31

No results posted yet for this study

Summary

Remifentanil is a potent opioid widely used during the administration of general anesthesia. There is a lot of evidence that suggest that the used of remifentanil is associated with the development of hyperalgesia (a reduction of nociceptive thresholds). However, the mechanism of this hyperalgesia is not fully understood.

Recently, it was demonstrated that the disruption of the Cl- homeostasis could be involved. Interestingly, this was prevented in a murine model with the administration of Acetazolamide, a carbonic anhydrase inhibitor. In our clinical trial we will try to determine if the preoperative administration of acetazolamide could prevent the hyperalgesia induced by remifentanil in patients scheduled for thyroidectomy with general anesthesia.

Conditions

  • Hyperalgesia
  • Opioid-Related Disorders

Interventions

DRUG

Acetazolamide

DRUG

Placebo Oral Tablet

Sponsors & Collaborators

  • University of Chile

    lead OTHER

Principal Investigators

  • Rodrigo Gutierrez, MD · Anesthesia Department, University of Chile

  • Antonello Penna, MD PhD · Anesthesia Department, University of Chile

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2018-09-28
Completion
2018-09-28

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02992938 on ClinicalTrials.gov